Clonal Cytopenia of Undetermined Significance

Search with Google Search with Bing
Information
Disease name
Clonal Cytopenia of Undetermined Significance
Disease ID
Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT06240754 Not yet recruiting Phase 2 Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial June 30, 2024 June 30, 2026
NCT03418038 Recruiting Phase 2 Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia March 23, 2018 March 2026
NCT04102423 Recruiting CHIP/CCUS Natural History Protocol March 3, 2020 September 15, 2033
NCT04902833 Recruiting Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms February 1, 2022 December 31, 2025
NCT05030441 Recruiting Phase 2 Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 April 1, 2022 June 30, 2026
NCT02958462 Recruiting N/A Pre-myeloid Cancer and Bone Marrow Failure Clinic Study January 16, 2017 September 15, 2035
NCT05483010 Recruiting Phase 2 Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS) February 19, 2024 May 31, 2027
NCT05641831 Recruiting Phase 2 Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study February 6, 2023 December 31, 2028
NCT06063486 Recruiting Phase 2 Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms March 1, 2024 March 1, 2027
NCT05102370 Recruiting Phase 1 A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance October 6, 2021 October 6, 2025